by Maria Zannes | Aug 11, 2020 | News
AUGUST 11, 2020 As published in the San Antonio Business Journal By W. Scott Bailey – Senior Reporter, San Antonio Business Journal A local pathology practice has initiated a validation study of San Antonio-based bioAffinity Technologies’ CyPath Lung early...
by Maria Zannes | Sep 6, 2019 | Articles, News
AUGUST 29, 2019 As published in the San Antonio Business Journal By W. Scott Bailey – Senior Reporter, San Antonio Business Journal While there is acknowledgment that women have made progress in their climb to executive-level positions in San Antonio’s...
by Maria Zannes | Mar 6, 2019 | News
BioAffinity Technologies is proud to be named a finalist in the Lyfebulb Helsinn 2019 Innovation Summit in Oncology. Lyfebulb-Helsinn Innovation Summit March 18 and 19, 2019 Monaco, Principality of Monaco Ten finalists will compete at the second annual...
by Maria Zannes | Oct 12, 2018 | News
OCTOBER 10, 2018 As published in Genome Web’s 360Dx NEW YORK, NY – BioAffinity Technologies today said that it has inked a licensing agreement with Precision Pathology Services for the continued development and commercial sale of its CyPath Lung assay as a...
by Maria Zannes | Oct 12, 2018 | News
OCTOBER 10, 2018 As published in the San Antonio Business Journal By W. Scott Bailey – Senior Reporter, San Antonio Business Journal BioAffinity Technologies, a San Antonio-based biotech, has struck a deal with another local company, Precision Pathology Services, to...
by Maria Zannes | Jul 24, 2018 | News
JULY 20, 2018 As published in GenomeWeb’s 360Dx By Leo O’Connor NEW YORK – BioAffinity Technologies has begun clinical validation of a test for the early detection of lung cancer that uses flow cytometry and detects porphyrin molecules in sputum samples. The San...
